Literature DB >> 23560639

Patient-reported outcomes of 182 adults with severe haemophilia in Germany comparing prophylactic vs. on-demand replacement therapy.

W Mondorf1, W Kalnins, R Klamroth.   

Abstract

Clotting factor replacement therapy has a major impact on the quality of life in patients with haemophilia. To analyse and compare the outcomes of on-demand and prophylactic treatment regimens in child- and adulthood, a self-evaluation questionnaire was sent to 182 patients over 30 years of age with severe haemophilia A or B. Analysis of the questionnaire results revealed that most study participants had been treated on-demand in childhood, but that the majority of these patients subsequently switched to prophylaxis. However, of those patients who began with prophylaxis as children, the vast majority maintained prophylactic treatment as adults. Inhibitor development was reported significantly more frequently by patients who started with on-demand treatment than by those who started with prophylaxis. In the year prior to completing the questionnaire, adults with severe haemophilia who received prophylactic treatment reported a significantly lower incidence of bleeding as a result of more frequent factor consumption. These results are in close accordance with published prospective data. Although nearly all patients with severe haemophilia had joint pain due to bleeding, those who had always had prophylactic treatment reported superior outcomes in terms of the need for joint replacement, walking speed and distance, participation in school sports and further education. These data clearly underline the superiority of prophylactic treatment for the majority of individuals with severe haemophilia. The worst outcomes were found in those treated on-demand in childhood who later switched to prophylaxis. In contrast to most studies which have compared treatment regimens on the basis of data from healthcare professionals, this study reflects treatment outcomes from the patient's perspective.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23560639     DOI: 10.1111/hae.12136

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

Review 1.  Molecular approaches for improved clotting factors for hemophilia.

Authors:  Randal J Kaufman; Jerry S Powell
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

2.  Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).

Authors:  K Kavakli; R Yang; L Rusen; H Beckmann; D Tseneklidou-Stoeter; M Maas Enriquez
Journal:  J Thromb Haemost       Date:  2015-03       Impact factor: 5.824

3.  The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.

Authors:  Tarek Owaidah; Abdulkareem Al Momen; Hazzaa Alzahrani; Abdulrahman Almusa; Fawaz Alkasim; Ahmed Tarawah; Randa Al Nouno; Fatima Al Batniji; Fahad Alothman; Ali Alomari; Saud Abu-Herbish; Mahmoud Abu-Riash; Khawar Siddiqui; Mansor Ahmed; S Y Mohamed; Mahasen Saleh
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

4.  Predictors of quality of life among adolescents and young adults with a bleeding disorder.

Authors:  John M McLaughlin; James E Munn; Terry L Anderson; Angela Lambing; Bartholomew Tortella; Michelle L Witkop
Journal:  Health Qual Life Outcomes       Date:  2017-04-07       Impact factor: 3.186

5.  Patient and parent preferences for characteristics of prophylactic treatment in hemophilia.

Authors:  Roberto Furlan; Sangeeta Krishnan; Jeffrey Vietri
Journal:  Patient Prefer Adherence       Date:  2015-11-23       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.